Latest Medical Technology News

Tetratherix Limited has marked a pivotal quarter with a $25 million ASX listing, an exclusive licensing agreement with Bio Optix for ophthalmic devices, and progress on FDA regulatory submissions for its prostate spacer product.

4DMedical has renewed its three-year contract with the University of Michigan Medical Center, reinforcing its foothold in US respiratory imaging. Alongside, a pivotal clinical study validates its technology’s ability to detect early lung disease, while a substantial Australian grant boosts its AI research.

ImpediMed has doubled its US unit sales in Q4 FY25, achieving a record total contract value and securing an additional $5 million tranche under its growth capital facility.

Pharmx Technologies has resumed trading on the ASX following the renewal of its pivotal National Diabetes Services Scheme agreement, signaling stability for the healthcare tech firm.

Echo IQ has secured a pivotal reseller agreement with US-based SARC MedIQ, unlocking access to over 300 healthcare facilities and accelerating adoption of its AI-driven EchoSolv AS technology across the American cardiology landscape.

Imagion Biosystems has received encouraging feedback from the FDA on its planned Phase 2 HER2 breast cancer clinical trial, paving the way for its Investigational New Drug application submission later this year.

Artrya Limited has secured a five-year, US$0.6 million contract with Tanner Health, marking its inaugural commercial revenue in the U.S. market for its AI-powered Salix Coronary Anatomy platform.

Nova Eye Medical has reported a record A$28.8 million in revenues for FY25, driven by strong US sales and sustained growth of its flagship iTrack™ Advance device.

Echo IQ has initiated a pivotal clinical validation study with the Mayo Clinic Platform to test its EchoSolv HF software, marking the final step before its planned FDA submission in late 2025.

Artrya Limited announces a strategic leadership reshuffle with co-founder John Konstantopoulos stepping into the CEO role as the company prepares for its U.S. commercial launch of the Salix® AI-powered platform.

Next Science Limited has agreed to sell most of its assets to Demetra Holdings for US$50 million, with plans to return an estimated US$30 million net proceeds to shareholders pending approval.

Optiscan Imaging Ltd has commenced a landmark clinical study at Royal Melbourne Hospital, testing its cutting-edge InVue® and InForm™ devices to improve breast cancer surgery precision. The study aims to generate critical data for US FDA approval and could redefine surgical oncology workflows.